This chapter should be cited as follows: This chapter was last updated:
Bronson, R, Glob. libr. women's med.,
(ISSN: 1756-2228) 2011; DOI 10.3843/GLOWM.10329
July 2011


Immune Aspects of Infertility

Richard A. Bronson, MD
Professor of Obstetrics & Gynecology and Pathology and Director of Reproductive Endocrinology, Department of Obstetrics and Gynecology; Chief of the Andrology Laboratory, Department of Pathology, Stony Brook University Medical Center, Stony Brook, New York, USA


Spermatozoa have an unusual relationship with the immune systems of both men and women. Although they are produced by men, they bear new developmental antigens to which the male immune system is not tolerant. In women, spermatozoa periodically invade their bodies as foreigners. Spermatogenesis begins during puberty, long after the immune system has learned to distinguish the antigenic expression of its own tissues and extracorporeal antigens. Despite the occurrence of new developmental antigens on sperm,1 an autoimmune response against spermatozoa is uncommon, occurring only in approximately 7–8% of unselected men from infertile couples.2

After their intravaginal deposition, spermatozoa pass through various compartments of the female reproductive tract that are capable of mounting an immune response yet fail to elicit one.3, 4 Clues to both the male's and female's lack of immunologic responsiveness to sperm reside within the immune system itself. Immunosuppressive factors exist within seminal fluid, and a population of T-suppressor lymphocytes has also been detected both within seminal fluid and in the interstitium of the testis and the submucosal regions of the epididymis.5, 6

It has been known since the late 19th century that spermatozoa are antigenic and that experimental animals can be immunized with sperm.7, 8 In nonhuman species, these immunized animals exhibit diminished fertility.9, 10, 11 Although preliminary evidence suggested an association between the presence of circulating antisperm antibodies in men and women and infertility, it has only been in recent decades that many of the concepts dealing with immune-mediated reproductive impairment have been clarified.

The concept of immunologic infertility stems from several key observations. It was demonstrated in the 1950s that autoimmune responses to sperm and testis antigens had immunologic consequences. Guinea pigs immunized with homologous testis antigens in complete Freund's adjuvant developed autoimmune responses to the antigens, leading to orchitis and aspermatogenesis.12 The clinical relevance of antisperm autoimmunity became apparent in 1959, when spontaneous agglutination of ejaculated sperm and serum antisperm antibodies were observed in infertile men by Rumke and Hellinga.13 During the same period, Franklin and Dukes14 noted the presence of sperm agglutinating activity in sera of women with unexplained infertility. This was soon followed by the detection by Fjallbrant15 and Isojima and colleagues16 of serum antisperm antibodies that promoted complement-dependent sperm immobilization in infertile women. When endocrinologic problems of ovulation, sequelae of genital tract infections, and abnormalities of sperm production are excluded, there remain a substantial number of patients with idiopathic infertility. In this group, antisperm antibodies appear to have an important etiologic role.17


Proof that antisperm antibodies have a role in infertility requires documentation of their presence in sera of men and women, demonstration of these immunoglobulins bound to the sperm surfaces, as well as evidence of an alteration in the ability of such immunoglobulin-coated sperm to function – that is, to enter the female reproductive tract and either to reach the site of fertilization or to fertilize eggs.

Until the late 1970s, most laboratories attempted to diagnose immunities to sperm by using one of three major forms of serologic tests: sperm agglutination (either macroscopic or microscopic), complement-dependent sperm immobilization, or indirect immunofluorescence. Although several studies documented a clear difference in the prevalence of antisperm antibodies in sera of infertile couples as compared with fertile men and women, other studies could not make this distinction between groups. The range of positive results for agglutination assays has varied from 2% to more than 30%, with a large overlap between fertile and infertile groups (Table 1). Although complement-dependent immobilization provided more discriminating power, in that the incidence of false-positive results was far lower in sera of fertile men and women, this test suffered from an inability to detect noncomplement-fixing immunoglobulins, such as IgA.18, 19 Also important was the realization that naturally occurring antisperm antibodies exist in many species, including humans, at low titer. The sera of approximately 60% of men and women possess immunoglobulins that react with sperm, as detected by indirect immunofluorescence.20 These naturally occurring antibodies are readily absorbed by spermatozoa and testicular extracts but not by other human tissue. Of importance, they do not stain the surface of viable sperm in suspension but rather are directed against intracellular antigens of methanol-fixed permeabilized sperm. In one study, sera possessing antiacrosomal antibodies, when absorbed with bacteria of several species, no longer reacted with sperm. These naturally occurring antisperm antibodies have been shown to be present at only low titer (only 3 of 80 sera were positive at 1:16 or greater).21 In contrast to their high incidence in the general population, antibodies directed against antigens of the sperm surface, as detected by agglutination tests, mixed agglutination reaction, and immunobead binding, are uncommon and present at high titer in less than 10% of infertile men and women.22

Table 1. Range in antisperm antibodies detected in sera by different laboratories



Fertile (%)*

Infertile (%)*





Macroagglutination (GAT)





Microagglutination (FD or TAT)





Complement-dependent immobilization (SIT)





* Numbers reflect range.
GAT, gelatin agglutination test; FD, Franklin-Dukes; TAT, tray agglutination test; SIT, sperm immobilization test.
(Adapted from Beer AE, Neaves WB; Antigenic status of semen from the viewpoints of the male and female. Fertil Steril 29:3, 1978. Reproduced by permission of the publisher, The American Fertility Society.)


Methods for Detecting Antisperm Antibodies on Sperm

Several methods are now clinically available to determine whether spermatozoa themselves are coated with immunoglobulins. These include a direct antiglobulin assay using 125I radiolabeled heterologous antibodies, a direct enzyme-linked immunosorbant assay (ELISA), mixed agglutination reaction, and immunobead binding.23, 24, 25, 26 Although each of these tests allows one to determine, in a semiquantitative way, the extent of autoimmunity to sperm, immunobead binding in particular provides a measure of the proportion of spermatozoa in the ejaculate coated with each of three immunoglobulin classes (IgG, IgA, and IgM). The precise amount of immunoglobulin associated with an individual spermatozoan surface, however, still cannot be determined by current methods.

Immunobead binding uses micrometer-size plastic microspheres to which antibodies produced against human antibodies are chemically coupled.27 The antihuman antibodies on the immunobead surface bind to the human antibodies present on the sperm surface. Hence, they act as antibody detector particles, which can be visualized with an ordinary microscope. This test can be used to analyze sperm recovered from semen specimens and can be used indirectly to study serum for the presence of antisperm antibodies. In the latter case, spermatozoa must first be documented free of antibodies on their surface, by a direct immunobead assay. They are incubated in serum at various dilutions and subsequently washed free and retested to determine if they have acquired antibodies on their surface during this time. Immunobead binding allows one to determine the proportion of sperm that is coated with antibodies, the region of the sperm surface to which antibodies bind (head versus tail), and the immunoglobulin class (IgG, IgA, or IgM) of antibody present.


Antibodies that mediate sperm immobilization through their interaction with complement were initially described by Fjallbrant in 196815 and Isojima and colleagues in 1968.16 In these assays, sperm are washed and incubated with serially diluted heat-inactivated test serum or secretions. A source of complement, usually guinea pig serum, is added. A time end point for immobilization of 90% of sperm or the percentage of motile sperm at a standard time is compared microscopically with sperm incubated with control sera and complement alone. Complement-dependent immobilization, although highly specific in that false-positive reactions are uncommon, does not detect the presence of non-complement-fixing immunoglobulins, such as IgA. The amount of antibody present in the sperm surface also appears to have a role in the extent of complement-dependent immobilization (Table 2).19 Hence, results obtained from these tests have a definite relationship to immunologic infertility and are highly specific. However, not all antisperm antibodies are detected. In addition, because seminal plasma contains complement inhibitors, complement-dependent cytotoxicity tests cannot be applied to detection of autoantibodies to sperm in semen.

Table 2. Relationship between antisperm antibody IgG binding and motility*

Extent of antisperm antibody IgG binding along sperm tail

Percentage motility* (number of sera tested)

No binding

86.4 ± 1 (40)

Tail tip

81.1 ± 3.9 (10)

1/5 principal piece

62 ± 6.8 ( 7)

2/5 principal piece

 8 ± 3.4 (10)

3/5 principal piece

 1 ± 1 (10)

* Expressed as mean ± standard error of the mean; following a 4-hour incubation with guinea pig serum
(Adapted from Bronson RA, Cooper GW, Rosenfeld D: Correlation between regional specificity of antisperm antibodies to the spermatozoa surface and complement-mediated sperm immobilization. Am J Reprod Immunol 2:222, 1982.)

Agglutination tests are a relatively insensitive means of detecting antisperm antibodies, because a relatively large number of immunoglobulins must be present on the spermatozoan surface to lead to cross-linking of highly motile sperm (Table 3).28 The two main procedures for sperm immobilization are the gelatin agglutination tests of Kibrick and colleagues29 and the microagglutination test of Friberg.30 Failure to give careful attention to controls can ultimately lead to misleading results, and nonspecific agglutination can occur in undiluted or only minimally diluted serum.31

Table 3. Comparison between results on male sera with immunobead binding technique* (Lab I) and tray agglutination test (Lab II)

Tray agglutination

Immunobead binding technique


Low binding

Intermediate binding

High binding

Negative (titer 4)





Titer 4–8





Titer 16–32





Titer 64–128





Titer 256





* Results in immunobead binding recorded to the highest binding observed for any immunoglobulin class.
(Adapted from Bronson RA, Cooper GW, Hjort T et al: Anti-sperm antibodies detected by agglutination, immobilization, microcytotoxicity and immunobead binding assays. J Reprod Immunol 8:279, 1985.)

Although a number of ELISAs had been developed to detect the presence of antisperm antibodies in serum, this approach has not proved satisfactory. A high incidence of naturally occurring sperm-reactive antibodies in the sera of fertile men and women of all ages has posed a major problem of distinguishing this immunologic background noise from those antibodies reacting with fertilization-related antigens on the sperm surface.32 The method of fixing sperm is critical in determining which antigens are presented to the test serum sample.33 A marked variation in the ability of ELISA to detect sperm-reactive antibodies has been documented when sperm were fixed in various manners (Table 4). Because this assay lends itself clinically to rapid analysis of larger numbers of sera, it has been a favorite in commercial laboratories. Results, however, have not always been shown to correlate well with clinical status.34

Table 4. Comparison of antisperm antibodies detected by immunobead binding then tested by ELISA using different methods of sperm fixation


Patient sera


Immunobead binding results


Sera reacted first with live motile sperm then glutaraldehyde fixed


Sera reacted with fresh sperm glutaraldehyde fixed


Sera reacted with fresh sperm air dried


Sera reacted with frozen sperm glutaraldehyde fixed

































































































The immunoglobulin classes of sperm-reactive antibodies detected by immunobead binding and ELISA were comparable only when live sperm were incubated in test serum before fixation, indicating that fixation of spermatozoa had altered their antigenicity. +, detected; -, undetected.
(Adapted from Bronson RA, Cooper GW, Witkin SS: Detection of spontaneously occurring sperm-directed antibodies in infertile couples by immunobead binding and enzyme-linked immunosorbent assay. Ann NY Acad Sci 438:504, 1984.)


An important clue in understanding how immunities to sperm can affect reproduction was the correlation demonstrated between the titer of circulating antisperm antibodies and both the duration of time to conception and the chance of conception. Rumke and associates showed in monitoring untreated men with autoimmunity to sperm during a 15-year period that the chance of conception declined markedly when the titer of circulating antisperm antibodies rose in blood to 1:128 and fell to zero at titers of 1:1024 and greater.13 These observations suggested that as the concentration of circulating antibodies rose, the chance of their appearance in seminal fluid increased, consistent with the fact that immunoglobulins of the IgG class enter semen as transudates from serum. Autoimmunities to sperm then occur on a continuum. Their effect on an individual's fertility depends on the titer of circulating antibody, the immunoglobulin class of these antibodies, and the antibody specificity for specific antigens.

The amount of immunoglobulin bound to the sperm surface at the time of ejaculation depends on several factors: the concentration of antisperm antibodies within the prostate and seminal vesicle secretions; the local production of antibodies within the reproductive tract, compared with their transudation from blood; the binding of antibodies to sperm as they transit the epididymis before ejaculation or, conversely, when they mix with seminal fluid; the elasped time since the last ejaculation; and the affinity of different antibody molecules for various antigens on the sperm surface. Hence, the amount of immunoglobulin on the sperm surface reflects the final common pathway of several mechanisms of immunoglobulin secretion. Evidence supporting the importance of studying sperm in the ejaculate directly, in making the diagnosis of autoimmunity to spermatozoa, comes from a comparison of sperm antibodies detected in matched semen and serum specimens.35, 36 In approximately 15% of cases, antibodies have been detected in serum but not on the sperm surface. The majority of these circulating antisperm antibodies that failed to enter seminal fluid were of low titer and directed against the sperm tail tip. In addition, antisperm IgM does not enter the male genital tract secretions, even when present in high concentration in blood. This immunoglobulin class of antisperm antibodies is only rarely encountered in sera of heterosexual men, though it is more common both in homosexual men and sera of women.37

Circumstantial evidence has accumulated suggesting the production of locally secreted antisperm antibodies, within the genital tract, despite their absence in blood. These immunoglobulins are primarily of the IgA class. Secretory IgA is the major immunoglobulin present in tears, saliva, and colostrum, as well as in respiratory, gastrointestinal, and reproductive tract secretions.38 It is the product of two distinct cell types. Secretory IgA is synthesized by plasma cells, and epithelial cells produce secretory component, which act as a regulatory transport protein for IgA.39 A membrane SC–IgA complex forms and is then internalized and transported to the apical region of epithelial cells. The SC–IgA complex is then released into the external secretions. Although little is known about the mechanism of IgA secretion within the male genital tract, clear evidence shows the local production of Escherichia coli-specific IgA in men with chronic prostatitis.40 A local secretory system exists in the human female reproductive tract, as suggested by the prominence of IgA-producing plasma cells in the fallopian tubes, cervix, and vagina.41 In an immunofluorescence study, Kutteh and colleagues demonstrated that tubal segments obtained at sterilization contained IgA plasma cells in the subepithelial lamina propria.42 These considerations suggest that if one relies solely on serologic tests to diagnosis immunities to sperm, results would be misleading in a sizable proportion of cases. The data enforce the notion that the presence of humoral antibodies directed against sperm is not relevant to fertility unless the circulating antibodies are present within the reproductive tract. As a corollary, tests capable of detecting immunoglobulins on living sperm recovered from the ejaculate are the most direct way to detect whether autoimmunity to sperm exists and, if so, to determine its extent and type.

The diagnosis of clinically relevant immunity to sperm in women is difficult, given our current inability to adequately sample secretions of the uterus and fallopian tubes. In addition, immunoglobulin secretion within each of the reproductive compartments (cervix, uterus, fallopian tubes) is under hormonal control and exhibits different mechanisms in the regulation of antibody transport. As an example, estradiol lowers the content of immunoglobulins within cervical mucus while stimulating the active transport of IgA and transudation of IgG into the uterine lumen.43 To add to the complexity, men may secrete blood group substances in their ejaculate, and these adsorb to spermatozoa. Antiblood group antibodies present in a woman's serum could in theory bind to these spermatozoa, giving a false-positive result. Indeed, we have presented evidence that certain antisperm antibodies of the IgM class are reactive with oligosaccharides common to the blood group substances.44 In our study of sera from known fertile women, supplied by the World Health Organization (WHO) reference bank, 40% contained immunoglobulins that reacted with spermatozoa,45 usually the tail end piece. These results suggest that there is a continuum in the extent of immunity to sperm and that those mechanisms in women that prevent immunization to paternally derived antigens are imperfect. Hence, care must be exercised in distinguishing between a 'positive' result and a clinically significant result, whether based on immunobead binding or any antisperm antibody assay. It is clear that results of these tests should not be interpreted in the absence of clinical correlates. This is true despite the development of better antisperm antibody assays and increasing laboratory evidence that these phenomena may lead to infertility.46


Both spermatozoa and the mature oocytes are short-lived cells that only transiently make their appearance, in a periodic manner, within the female reproductive tract. Their interaction, if successful, may lead to the development of a zygote, initiating a potential chain of events resulting in successful reproduction47. The evanescent nature of gametes, however, makes them especially susceptible to immunologically mediated damage. Antisperm antibodies (ASA) have been shown to be directed against several different antigens, and each would be expected to have different effects on sperm functions. At least six different major immunodominant antigens have been detected on human sperm, recognized by human sera containing antisperm antibodies.48 Indeed, several studies have shown various effects of antisperm antibodies at the level of the zona pellucida and the egg surface. Hence we, and Aitkin and colleagues, have shown that antisperm antibodies might either inhibit, promote, or be neutral in their effects on the ability of human sperm to penetrate zona-free hamster eggs (Table 5).49, 50 In addition, different sperm head-directed antibodies exhibit various effects on the ability of human sperm to penetrate the human zona pellucida. Using a hemizona assay, Mahony and associates assessed the effects of labeling sperm from known fertile men with antisperm antibodies.51 The power of this approach is to eliminate the variation in sperm binding between men and zonae.52 Immunobead binding was used to confirm that at the serum dilution chosen which minimized sperm agglutination, nearly all sperm were labeled with immunoglobulin over the heads. Salt-stored hemizonas from the same egg were inseminated with antibody-free or antibody-labeled sperm from the same donor. A wide range in effect was observed, several sera markedly lowering the number of tightly bound sperm observed after serial zona washing, whereas other sera were completely without effect (Table 6). These results further emphasize that the functional effects of antisperm antibodies in different individuals may vary despite their same regional localization of binding on the spermatozoan surface. These observations emphasize the need for more specific tests that allow one to determine the antigenic moieties against which antisperm antibodies are directed.

Table 5. Effects of head-directed ASA bound to the plasma membrane on sperm-egg penetrating ability


Time after insemination (min)

Percentage eggs penetrated (penetrating sperm/inseminated egg)


ASA negative

ASA positive






13.3 (2/15)


30 (3/10)


0 (0/12)


100 (89/20)




77.8 (11/9)


100 (12/8)


37.5 (4/8)


100 (142/24)




92.3 (26/13)


100 (24/9)


54.5 (6/11)


100 (113/14)




100 (76/23)






100 (356/28)


All experiments were performed with spermatozoa from the same known fertile donor. Each ASA-positive serum (Br, Eb, Gr) was judged against the ASA-negative control. ASA were transferred to donor sperm in vitro, and then antibody-labeled spermatozoa were washed free of serum before overnight incubation and insemination.
(Adapted from Bronson RA, Cooper GW, Phillips DM: Effects of antisperm antibodies on human sperm ultrastructure and function. Hum Reprod 4:653, 1989.)

Table 6. Effects of ten sera containing sperm head-directed antibodies on the ability of human sperm to bind to salt-stored human zona pellucida

Serum status

Number of sera

Percentage inhibition of binding

Hemizona index*

Antibody negative



94.6 (89–99)

Antibody positive





87.9 (85.4–91.6)



55.3 (54.4–56.1)



30 (18.1–46.2)

Hemizona Index = (Number of antibody-coated sperm bound to hemizona / Number of antibody-free control sperm bound to hemizona ) x 100.
(Adapted from Mahony MC, Blackmore PF, Bronson RA, Alexander NJ: Inhibition of human sperm-zona pellucida tight binding in the presence of antisperm antibody positive polyclonal sera. J Reprod Immunol 19:207, 1991.)


The proportion of ejaculated sperm that is coated with immunoglobulin varies markedly among men.53 For instance, in 154 men found to have autoimmunity to sperm as judged by direct immunobead binding, 52% had greater than 90% of their sperm bound, 23% had 50–90% bound, and the remaining quarter had less than half of their sperm coated with antibodies. Because sperm that are antibody bound over most of their surfaces are unable to enter cervical mucus54 (antibody binding to the sperm tail tip being a possible exception55), yet they remain completely motile in semen, several studies have shown a relationship between antisperm antibodies and impaired results of postcoital tests.56, 57 We have found an inverse correlation between the proportion of sperm that is coated with immunoglobulin and the number of sperm present within the cervical mucus after sexual relations (Table 7). When all sperm are coated with immunoglobulin, it is rare to find one to two sperm per high-power field within well-estrogenized cervical mucus, despite the presence of hundreds of millions of motile spermatozoa in the ejaculate. However, as the proportion of antibody-coated sperm declines below 50%, as judged by immunobead binding, the numbers of motile sperm observed in cervical mucus increase. Hence, it appears that men who have high levels of autoimmunity to sperm, as reflected in the proportion of immunoglobulin-coated sperm in their ejaculates, appear to be functionally oligospermic. That is, their sperm cannot enter the reproductive tract, and the chance that they will reach the environs of the egg is diminished.

Table 7. Correlation between extent of autoimmunity and number of motile spermatozoa in cervical mucus at postcoital testing*

Percentage antibody-bound sperm in ejaculate detected by immunobead binding

Total number of motile sperm in ejaculate × 106

Number of motile sperm/high-power field in postcoital cervical mucus


































>50% but <100%







































*Cervical mucus was examined within 48 hours preceding the thermal shift 8–12 hours after coitus. Wives were free of sperm-directed antibodies.
†Spermatozoa in cervical mucus are listed as the average observed or as a range in high-power field (x400).
(Bronson RA, Cooper GW, Rosenfeld DL: Autoimmunity to spermatozoa: Effect on sperm penetration of cervical mucus as reflected by postcoital testing. Fertil Steril 41:4, 1984. Reproduced with permission of the publisher, The American Fertility Society.)

This impairment of cervical mucus penetrating ability appears to be mediated through the Fc portion of the immunologlobulin molecule. Hence, sperm exposed to Fab preparations of antisperm IgG are able to swim through cervical mucus, whereas those labeled with intact antibody do not.58 Similarly, immunoglobulins of the IgA class bound to the sperm surface can be degraded by an IgA1 protease derived from Neisseria gonorrhoeae that cleaves the heavy chain at amino acid bond 235–236 of the hinge region.59 In this manner, the Fc portion of IgA is liberated from the sperm surface. These protease-treated sperm, although still coated with IgA Fab, showed an improved ability to penetrate into and sustain motility within cervical mucus (Table 8). On this basis, we have postulated that a solid-phase component of cervical mucus possesses a yet unidentified receptor for a ligand on the Fc portion of the immunoglobulin molecule. That this effect is not species specific was demonstrated in a study of the effects of a number of antisperm monoclonal antibodies, raised in mice, on the ability of human sperm to penetrate bovine cervical mucus in vitro.60 Those monoclonal antibodies directed against epitopes present on the living sperm surface (as detected by immunobead binding) impaired sperm penetration through a column of bovine cervical mucus, whereas monoclonal antibodies directed against subsurface epitopes (detected by indirect immunofluorescence with permeabilized sperm) did not (Table 9).

Table 8. Effect of IgA1 protease treatment promoting the mucus-penetrating ability of coated human spermatozoa

Patient identification

Antisperm antibody isotype

Percentage of motile sperm penetrating a column of human cervical mucus in vitro


After protease


IgG > IgA




IgA > IgG








IgA = IgG




IgA >> IgG




IgA > IgG




IgA >> IgG












Antibody negative




Antibody negative




Antibody negative



(Adapted from Bronson RA, Cooper GW, Rosenfeld DL et al: The effect of an IgA1 protease on immunoglobulins bound to the sperm surface and sperm cervical mucus penetrating ability. Fertil Steril 47:987, 1987. Reproduced with permission of the publisher, The American Fertility Society.)

Table 9. Relationship between the extent of binding of monoclonal antibody (Mab) to motile spermatozoa and their ability to penetrate bovine cervical mucus in vitro

Mab reactivity as judged by % sperm binding immunobeads*

Number of samples

Location of vanguard spermatozoa (mm) + SD

100% sperm bound


17.5 ± 6.2

50 < 100%


27.3 ± 11.8



33.0 ± 11.7

No binding


37.4 ± 5.8

* A population of nearly 100% motile spermatozoa obtained by swim-up were incubated with monoclonal antibody then washed free of ascitic fluid or culture supernatant and exposed to immunobeads.
† Following 90 minutes incubation at 37°C.
(Adapted from Bronson RA, Cooper GW: Effects of sperm-reactive monoclonal antibodies on the cervical mucus penetrating ability of human spermatozoa. Am J Reprod Immunol 14:59, 1987.)

The presence of antisperm antibodies in women may also be associated with altered sperm motion within cervical mucus. Spermatozoa appear initially to gain entrance into the cervical mucus but then subsequently become immobilized, by either shaking in place, without forward progression, or being completely immobilized. The behavior of sperm within cervical mucus depends on the type of antibodies present within the mucus and their specificity for the sperm surface. Hence, high degrees of binding of non-complement-fixing antibodies to the sperm surface may result in sperm entrapment and shaking in place, whereas complement-fixing antibodies (when directed against the majority of the sperm tail) could also lead to immobilization. Levels of complement within cervical mucus are lower than those present in serum,61 and in fact, it may take as long as 6–7 hours for sperm immobilization to occur. Hence, overnight postcoital testing provides a clearer indication of antibody-mediated sperm damage than does a shorter interval (2 hours) after sex.

Current clinical assays for immunities to spermatozoa detect antidodies directed against epitopes of moieties on the spermatozoan surface. Recently, Veaute and associates developed an ELISA using truncated acrosin recombinant proteins as antigens for the detection of antibodies directed against acrosin, a trypsin-like protease present within the sperm acrosome 62. Anti-acrosin antibodies were detected in sera from 34 of 179 women (19%) who had consulted for infertility. Detection by immunobead binding of antibodies directed against sperm surface antigens resulted in a similar incidence (36 of 179), although only six of them showed correspndence between assays. Anti-acrosin antibodies inhibited proacrosin binding activity to a recombinant zona pellucida protein A in vitro, as well as acrosin activation.


During the onset of spermatogenesis, at puberty, new developmental antigens make their appearance on the sperm surface.63 As immune tolerance for self-antigens is established in the neonatal period, these newly appearing sperm antigens may be immunogenic. It has been theorized that sequestration of developing sperm, behind the blood-testis barrier formed by tight junctions of Sertoli cells, prevents the generation of autoantibodies to sperm.64 Additional evidence now indicates that some testicular autoantigens are accessible to circulating antibodies and to immune processing cells.65, 66 A population of suppressor T lymphocytes has been identified in the epididymis by immunoperoxidase staining with monoclonal antibody probes to T-cell surface antigens.5, 6 These putative T-suppressor lymphocytes may have an active role in preventing the development of autoimmunity to sperm.67 (See section on Vasectomy and Autoimmunity to Sperm.)


Although women are regularly 'inoculated' intravaginally with spermatozoa during coitus, this event is usually not associated with the development of immunity to sperm. Yet the female reproductive tract is not an immunologically privileged site, as demonstrated by the presence of anti-Candida antibodies in women with yeast vaginitis.3 Experimental intravaginal inoculation with poliovirus in women has been shown to lead to the formation of locally produced antiviral antibodies in vaginal secretions.4 

 Immunoinhibitory substances have also been detected and partially characterized in seminal plasma; they may protect sperm from immunologic damage and prevent sensitization of a woman to sperm antigens after coitus.68, 69, 70 A potent immunosuppressive agent, 19-hydroxy prostaglandin E, has been found in the seminal fluid of men and subhuman primates.71 Other possible immunosuppressive factors include polyamines,72 transglutaminase,73 and high-molecular-weight Fc receptor binding protein similar to pregnancy-associated protein A.74 Spermatozoa themselves have been shown to be immunosuppressive in rodents.75 However, because semen samples in vasectomized males also exhibit immunosuppressive activity, this observation suggests that active components are derived not solely from testicular, epididymal, or spermatozoan origin. Extensive studies on fractions obtained by gel filtration of seminal fluid and chromatographic techniques support the view that the inhibitory effects of seminal plasma are due to a range of molecules of widely differing molecular weights and binding affinities for specific ligands. Research in this area has been difficult because of the diversity of immunomodulatory substances and the tendency of low-molecular-weight species to associate reversibly with high-molecular-weight components. The generation of cytotoxic polyamines following addition of calf serum to seminal plasma, in studies of immunosuppressive activity, has further confused the issue.76 However, using serum-free culture conditions illustrates clear evidence of interference by seminal fluid in the immune function of T cells, B cells, natural killer (NK) cells, and macrophages.77 The effects of human seminal plasma on immunologically active cells include a reduced ability to bind antigen and to differentiate or proliferate in response to mitogens, as well as a failure of phagocytosis in antibody-dependent cell lysis. Anticomplement activities have also been demonstrated.78 Could nature then provide the means, through the common exposure at coitus, to seminal fluid-derived suppressors, as well as spermatozoa, to prevent the development of immunity of sperm in women? Conversely, would the lack of immunosuppressor activity of seminal fluid lead to the development of antisperm antibodies? These intriguing questions, unfortunately, currently have no answer.

Recent studies have provided clues as to how spermatozoa might escape recogntion and immune-mediated destruction within the female reproductive tract. It has been theorized that human spermatozoa are susceptable to lysis by NK cells present within the reproductive tract, as they appear to lack major histocompatibility class I molecules.79 However, they may escape NK cell-mediated damage through the expression of Lewisx  and Lewis N-glycans on their surface, in a manner similar to tumor cells.80 Human seminal plasma also contains prostasomes, membranous vesicles secreted by epithelial cells of the prostate gland that can fuse with the sperm plasma membrane.81, 82 They have been shown to possess the complement inhibitors CD46 and CD59.83 In addition, when NK cells were co-cultured with purified prostasomes, their expression of CD244, an activating receptor, was diminished as shown by flow cytometry, as was their ability to degranulate and secrete interferon (IFN) gamma 84.


Evidence that spermatozoa share antigenic specificities with fertilized ova or cleaving embryos was initially provided experimentally in female animals immunized with sperm or testis cells. At serum dilutions permitting nearly normal fertilization rates, antisperm antiserum impaired embryo survival.85 Postfertilization effects of antisperm antiserum have also been demonstrated by the reduced survival of fertilized eggs transferred from oviducts of nonimmune rabbits to those of immunized pseudopregnant females.86 Uterine implantation rates of these embryos were one third to one half those in nonimmunized controls. In rabbits, antibodies raised against murine sperm have also been shown to react with early cleavage-stage mouse embryos87 and a number of antisperm monoclonal antibodies have been shown to react with antigens present on trophoblast cells.88

In theory, three mechanisms could account for the effects of experimentally induced antisperm antibodies and preimplantation embryo survival. Eggs may display sperm-derived antigens on the oolemma after fertilization.89 Embryonic antigens cross-reacting with sperm may be expressed during early embryonic development.90 Antisperm antibodies may indirectly affect embryonic development by stimulating the production of cytotoxic lymphokines from activated lymphocytes in the immune system of women sensitized to sperm.91

Although an anecdotal association between an increased risk of miscarriage and the presence of antisperm antibodies in women has been reported,92 there is at this time no clear evidence in humans that antisperm immunity causes abortions in clinically diagnosed pregnancies. For example, the risks of miscarriage in women who have antisperm antibodies and who conceive after intrauterine insemination (IUI) have been found to be no greater than in the general infertile population.93 However, these observations do not address the question of whether antisperm immunity can cause abortion during the interval between ovulation and implantation. Because pregnancy would not be clinically diagnosed in these cases, the manifestations of this event would be occult and would present as unexplained infertility rather than recurrent abortion. A single study of the likelihood of successful preimplantation embryonic development and subsequent pregnancy, in women with immunologic infertility undergoing in vitro fertilization (IVF), again raises this issue (see below).


Reproductive tract tissues contain diverse lymphocyte and macrophage populations, which can be activated and may alter reproductive functions. Increasing evidence suggests that soluble products of these cells can either inhibit or promote various endocrine, gamete, and nidatory events.94 Cell-mediated immunologic responses involve thymus-derived lymphocytes that are activated by antigenic stimulation and immunologic cytokines. Cytotoxic T cells can recognize and kill cells bearing foreign antigens by direct contact and by release of cytotoxic cytokines such as IFN gamma. Both the endometrium in the late luteal phase of the menstrual cycle and the decidua of early pregnancy contain numerous lymphocytes and macrophages.95, 96 Several studies have reported antisperm cell-mediated immune responses in infertile women. One study of endometrial T-cell subpopulations in infertile patients has revealed large numbers of activated T cells in some of these women.97 Patients with endometriosis have been found to have large numbers of activated macrophages and lymphocytes in their peritoneal fluid.

Soluble products of activated lymphocytes and macrophages, including the lymphokine IFN gamma and the monokine tumor necrosis factor (TNF), have been shown to affect human sperm motility and fertilization, as measured by the hamster egg penetration test.98 Secretion of these products and others within various regions of the female reproductive tract could affect sperm function. Various lymphokines and monokines have also been reported to exert adverse effects on the development of early mouse embryos in vitro.


Given evidence that impaired infertility can be induced experimentally by either active or passive immunization with zona pellucida proteins,99, 100, 101 several groups have attempted to determine whether such antibodies occur spontaneously in women.102, 103, 104, 105 Unfortunately, problems of methodology have continued to result in a failure to prove this thesis convincingly. Because the zona pellucida consists of a glycoprotein matrix capable of trapping immune complexes, the use of immunofluorescence to detect specific antibodies to intact zona antigens may lead to nonspecific reactions. Dunbar has shown that the production of immune complexes by freezing and thawing serum can give false-positive reactions from previously negative serum.106 Unfortunately, the majority of studies of humans have also used relatively undiluted serum, without concern for the specificity of the assay. Clinical studies have been diverse and contradictory (Table 10). Dunbar studied sera from many infertile women using a sensitive radioimmunoassay with well-characterized, purified zona antigens and failed to detect any antizona antibodies.106 Although it could be argued that these purified zona antigens have undergone alterations in their configuration such that native epitopes were lost, the presence of antizona autoantibodies in humans has not been confirmed.

Table 10. Incidence of anti-zona pellucida antibodies in sera of fertile and infertile women and men

Investigators and citation

Method of antibody detection

Clinical category and incidence of positive sera

Shivers and Dunbar102


Indirect immunofluorescence with whole porcine zonae

Infertile women 7/22 'control sera'

Sacco and Moghissi103




Indirect immunofluorescence with whole porcine zonae




Infertile females 21/50

Fertile females 18/30

Infertile males 18/35

Fertile males 4/10

Karuchi et al.104





Heat-solubilized 125I-labeled porcine zonae





Women with unexplained infertility 3/11

Women with amenorrhea 16/48

Fertile women 4/12

Fertile men 3/10

Kamada et al.105



Passive hemagglutination with bovine erythrocytes coated with porcine zona substance


Infertile women 8/88*

Fertile women 1/90

*All reactivity detected by passive hemagglutination lost after absorption of sera with porcine erythrocytes

Dakhno et al.107





Indirect immunofluorescence with whole porcine zonae





Fertile women 5/20

Women with unexplained infertility 7/24

Fertile males 6/11

Reactivity in all groups absorbed with porcine erythrocytes


ELISAs against purified porcine zona antigens

No reactivity detected in sera of infertile women


Obstruction of sperm egress has been associated with development of autoimmunity to spermatozoa. Vasectomy, by inhibiting sperm exit from the epididymis and proximal vas deferens, results in sperm antigen leakage and antisperm antibody production in approximately 70% of men.108, 109 Because unique auto-antigens are expressed on cells of the basal compartment of the seminiferous tubule, most investigators have speculated that autoimmunity to sperm after vasectomy broaches the sequestration of antigens as well as local immunoregulatory mechanisms. The presence of these antibodies within reproductive tract secretions, noted at the time of vasovasostomy, occurs infrequently and has been correlated with an impaired chance of subsequent fertility.110 Men with bilateral congenital absence of the vas deferens, epididymis, or seminal vesicles,111 as seen in cystic fibrosis,112 also are found to be at risk for immunity to sperm. Our finding that autoimmunity to sperm does not develop in these men until after puberty (Table 11)113 suggests that the immune system may become exposed to developmental antigens expressed on spermatozoa and spermatids to which it is not tolerant after activation of the pituitary–testicular axis and the initiation of spermatogenesis. Developmental abnormalities of the formation of the blood–testis barrier, its traumatic disruption, or unilateral focal cryptic intratesticular obstruction at the level of the seminiferous tubules, could therefore lead to antisperm antibody formation.

Table 11. Detection of antisperm auto-antibodies in 15 males with cystic fibrosis and their pubertal status


Patient category

Age (years, mean)

Testicular volume (mean ± SEM)

Serum testosterone (nmol/L mean ± SEM)

Serum FSH (miu/mL)

Antibody positive

26.4 (range 18–33)

20.0 ± 0.0

12.3 ± 1.4

12.5 ± 3.4

Antibody negative

12.4 (range 9–19)

7.0 ± 2.0

4.0 ± 1.7

4.6 ± 0.99


(Adapted from Bronson RA, O'Connor WJ, Wilson TA, Bronson SK, Chasalow FI, Droesch K. (1992) Correlation between puberty and the development of auto-immunity to spermatozoa in men with cystic fibrosis. Fertil Steril 58, 1199-1204.



The presence of circulating antibodies to continuously produce sperm antigens has raised the concern that vasectomy might result in immune complex disease.114 Immunologically mediated injury occurs when preformed immune complexes are deposited either in renal glomeruli or blood vessel walls. That an immune response need not be mounted for damage to occur has been shown when arteritis, endocarditis, and glomerulonephritis developed in normal animals infused with immune complexes. The formation of circulating immune complexes is dependent on both antigen and type of antibody (numbers of combining sites, size of immunoglobulin molecule, and molecular weight and charge of antigen). Large complexes formed in antibody access are rapidly removed, primarily by the Kupffer's cells of the liver. In contrast, complexes formed in antigen access will be of smaller size and may remain in the circulation. These may become widely disseminated and activate the complement cascade.115

Alexander has shown that antigen production continues after vasectomy and that entrapped sperm are engulfed by macrophages within the vas deferens.116 Sperm antigens may also leak from the reproductive tract. The efferent ducts of the testis in monkeys vasectomized one year earlier were found to have a significant increase in thickness, and 33% of these animals exhibited immune complexes within the thickened basement membrane.117 Granular deposits of both IgM and IgG, as well as the complement component C3, have been found in renal glomeruli of vasectomized animals. Vasectomized men have also been shown to have a higher incidence of circulating immune complexes than age-matched controls.118 Although some monkeys fed diets high in cholesterol after vasectomy developed atherosclerosis,119 several epidemiologic studies in humans have failed to substantiate an increased risk.120, 121


Effective treatment of immunities to sperm rests on the accuracy of diagnosis. Four approaches have been used to treat couples with antisperm antibodies. Condom 'therapy' is mentioned only to emphasize its ineffectiveness, in the presence of more active treatment approaches.122 Its value was never clearly documented in the past, and the psychological burden of using contraception when desiring pregnancy is great. The remaining approaches have included corticosteroids, intrauterine insemination (IUI), IVF, and gamete intrafallopian transfer (GIFT). However, the risk:benefit ratio in the use of corticosteroids is still not well known for either men or women. Preliminary evidence suggests that this treatment approach is relatively ineffectual. IUI, when carefully timed to follicular maturation in superovulated and hormonally and sonographically monitored cycles, results in an increased chance of pregnancy, but success rates at best are no greater than 35% within six treatment cycles. Although technically intense and expensive, if IUI fails, IVF offers the greatest likelihood of achieving fertilization, in the presence of both autoantibodies to sperm in men and circulating antisperm antibodies in women. Early evidence indicates that GIFT may also be effective in treating couples in whom the man has developed antisperm immunity.123 These results with the newer assisted reproductive techniques suggest that immunities to sperm impair the ability of spermatozoa to reach the site of fertilization within the fallopian tubes to a far greater extent than their ability to penetrate eggs, should the gametes meet in the presence of these antibodies.

Why treat in the absence of proof? The accumulated evidence from laboratory-based studies provides circumstantial evidence that immunities to spermatozoa can potentially impair processes leading to fertilization. However, there are currently no prospective studies demonstrating a decreased fecundity in those couples in whom antisperm antibodies are detected, when compared with couples in the absence of immunities to sperm. While we have maintained that such studies are needed as proof of immunological infertility,124 these data are not likely to be available in the near future. Given the low incidence of significant immunities to sperm in men and women (which are found in approximately 3–5% of unselected infertile couples), many centers will need to participate in a prospective study of the effects of antisperm antibodies on fertility, and patient acquisition will be slow. In addition, we have performed a retrospective analysis of pregnancies in women treated for infertility, whose husbands were found to exhibit an autoimmunity to sperm but were not themselves treated.125 Pregnancy rates varied from 15.3 to 66.7%, depending upon the proportion of spermatozoa coated with immunoglobulin, as judged by immunobead binding. The results suggest that the number of cases needed to obtain sufficient power to detect differences in fertility between antibody-positive and antibody-negative groups will be large.

Currently utilized tests, including immunobead binding, also do not identify those sperm-associated antigens to which antisperm antibodies are directed. Antibodies directed against different antigens would be expected to play differing roles in impairing processes leading to successful fertilization, and this appears to be the case. As noted earlier, when transferred to sperm of known fertile men, antisperm antibodies detected in sera of infertile couples have varying effects on gamete interactions in vitro, as judged by both hemi-zona assays and sperm penetration of zona-free hamster eggs. It is then currently difficult to select homogenous groups of couples with immunities to sperm for study. For these reasons, a prospective analysis of pregnancy rates of men or women with immunities to sperm is not possible at this time. I would argue, however, that one need not wait for clinical proof through prospective analysis of couples with immunities to sperm that they cause infertility, to recommend treatment. There is sufficient evidence garnered through laboratory investigation to suggest that these antibodies directed against sperm may alter their ability to enter the female reproductive tract and to successfully fertilize. The use of the immunobead binding test also provides useful information that allows the laboratory to optimize the preparation of spermatozoa for IUI (see below). 

A judgment as to whether an individual should be treated for immunity to sperm is far easier to make for men than for women. Spermatozoa are easily accessible for study. The degree of their impairment of penetrating ability of cervical mucus is directly related to the extent of autoimmunity. Men whose spermatozoa are all or nearly all (>70%) antibody-coated by at least one immunoglobulin class and fail to penetrate cervical mucus require treatment. When coated over the sperm head, not only do these sperm encounter difficulty penetrating cervical mucus, but should they reach the ampulla of the oviduct, fertilization may be impaired. Conversely, when less than 50% of sperm are antibody-bound, the number of sperm seen at postcoital testing is often no different from that of men without autoimmunity to sperm, and other causes of infertility should be investigated.

The diagnosis of clinically relevant immunity to sperm in women is more difficult, given our inability to adequately sample secretions of the uterus and fallopian tubes. Immunoglobulin secretion within the female reproductive tract is under hormonal control, and each of the reproductive compartments (cervix, uterus, fallopian tubes) exhibits different mechanisms in the regulation of antibody transport.126 As an example, estradiol lowers the content of immunoglobulins within cervical mucus while stimulating the active transport of IgA and transudation of IgG into the uterine lumen. While it would be ideal to evaluate tubal fluid or cervical mucus for the presence of sperm antibodies, this is not often possible. Extraction of antisperm antibodies from cervical mucus, a 'hydrogel', is difficult and may result in damage to these immunoglobulins.

A high incidence of ‘immunological background noise’ is also present in women. In our study of sera from known fertile women, supplied by the WHO reference bank, 40% contained immunoglobulins that reacted with the tail end piece of spermatozoa.28, 45 These results suggest that there is a continuum in the extent of immunity to sperm and that those mechanisms in women that prevent immunization to paternally derived antigens are imperfect. Hence, care must be exercised in distinguishing between a positive result and a clinically significant result, whether based on immunobead binding or any antisperm antibody assay. Results of these tests should not be interpreted in the absence of clinical correlates.

When sperm-reactive antibodies are present in serum, the postcoital test is impaired, and other causes of hostile cervical mucus have been excluded (occult cervicitis, altered pH, or poor cervical mucus production due to an insensitivity of mucus-secreting cells to estrogen stimulus, as seen in prenatal diethyistilbestrol exposure), the diagnosis of immunological infertility is strongly suggested. The finding of antisperm antibodies at the site of fertilization, within peritoneal fluid and in uterotubal flushings retrieved at laparoscopy, or in vaginal secretions or cervical mucus, reinforces the diagnosis of immunological infertility. In these women sensitized to sperm, large numbers of spermatozoa are often observed within cervical mucus, either immobilized or displaying restricted motion.

Observations from recent clinical experience in the treatment of immunological infertility reinforce the notion that the major locus of action of antisperm antibodies is through their impairment of sperm transport to the site of fertilization and their shortened longevity within the female reproductive tract. In those couples with antisperm antibodies who proceed with IVF, in vitro fertilization rates have been found to be high in the presence of circulating antisperm autoantibodies.127, 128, 129, 130 Only when nearly all sperm (>70%) are coated over their heads with immunoglobulin, as reflected in mixed antibody reaction (MAR) or immunobead binding assays, is there a significant fall in the likelihood of fertilization.131, 132 In the latter situation, the possibility exists that fertilization-related antigens (likely to be specific gamete receptors and their ligands) may be the targets of these antibodies. As the etiology of autoimmunity to sperm in men remains in large part unknown, treatments must be empirical, being directed not against the cause, but rather against the abnormal response. Evidence suggests that the use of corticosteroids for immunosuppression is relatively ineffectual, benefiting only approximately 20% of treated men133 (see below). When carefully timed to follicular maturation in superovulated, hormonally and sonographically monitored cycles, recent evidence suggests that IUI results in an increased chance of achieving pregnancy.

The rationale for IUI is to place within the uterine cavity a large population of living sperm that were excluded after coitus because of the presence of antisperm antibodies either on their surface or within cervical mucus. In theory, this would increase the likelihood that sperm might enter the fallopian tubes and reach the egg. Using careful sonographic and hormonal monitoring of follicular maturation, insemination can be timed to within a few hours of the expected ovulation. The accuracy of timing is important in that antibody-bound spermatozoa have a theoretically shortened survival time within the female reproductive tract, where they become opsinized by binding complement components, leading to either their phagocytosis by macrophages or their immobilization.134

There are no controlled, prospective studies of the efficacy of IUI in the treatment of infertility mediated by antisperm antibodies, in men or women. However, retrospective case reviews suggest that IUI is beneficial in conjunction with the use of clomiphene citrate or gonadotropin. The large study of Margalioth et al.93 illustrates this thesis. These authors reviewed the outcomes of IUI in a group of women with impaired postcoital tests who were also found to have antisperm antibodies in their sera. Monthly pregnancy rates in the first 3 months of treatment were 5% following IUI in the natural cycle, 9.7% following IUI in association with the use of clomiphene citrate, and 14.3% per cycle following gonadotropin stimulus and IUI. These differences were statistically significant (p <0.05). The majority of women conceived during three cycles of treatment, and 40% of women who failed to conceive in clomiphene-stimulated IUI cycles conceived with the subsequent use of gonadotropins. The likelihood of pregnancy was also lower for those women possessing sperm head-directed antibodies compared with those possessing antibodies directed against the spermatozoan tail. A recent large prospective study of infertile couples135 provides supporting evidence of these trends, in that pregnancy rates were highest following IUI in gonadotropin-stimulated cycles when compared with both clomiphene-stimulated and unstimulated cycles. Although one could argue that the presence of antisperm antibodies in serum does not in itself constitute proof of an immunological basis of infertility in women, and that other factors could have introduced bias in the study of Margalioth et al.93 the data do suggest the use of IUI in a limited trial in this clinical circumstance.

In a similar manner, IUI appears to be beneficial in men with autoimmunity to sperm, particularly when performed following the use of laboratory techniques in which ejaculation is performed directly into a buffer solution prior to sperm recovery. Sperm washing may provide some benefit, by eliminating low-affinity antisperm antibodies within seminal plasma that may have bound to spermatozoa during their residence within the vagina following coitus. Unfortunately, the affinities of immunoglobulins for antigens on the sperm surface are high, and once antibody binding to spermatozoa has taken place, simple sperm washing will not remove these antibodies from the sperm surface.136 Techniques that lead to dissociation of antibody–immunoglobulin complexes (low pH or high ionic strength) are associated with irreversible loss of sperm motility.

Ejaculation directly into a washing buffer appears beneficial in terms of both maximizing sperm recovery and minimizing the amount of antibody coating sperm.137, 138, 139 The process of antibody coating of sperm within semen is complex. Witkin6 has shown, in rabbits, that immunoglobulins may enter the male reproductive tract via the epididymis. If this is the case in humans, antibody coating of sperm may occur prior to ejaculation as well as thereafter. Conversely, immunoglobulins are also present in prostatic secretions13, 140 and sperm become exposed to them only after semen liquification. Rapid dilution of the ejaculate and mixing of semen could, in theory, be beneficial on this basis. In addition, transportation of semen collected at home to the laboratory prior to sperm processing would allow time for postejaculatory sperm antibody coating and agglutination, which would be avoided by processing semen immediately after ejaculation.

Pregnancy rates associated with IUI, in the treatment of men with autoimmunities to sperm, have improved substantially since adopting washing techniques requiring ejaculation of semen into medium rather than into dry containers. While older reports describe 3–10% per cycle rates of conception associated with IUI,141, 142 a later study of men with high levels of antisperm antibodies,143 and ejaculating into a buffered medium, described pregnancy rates of 64% following three cycles of IUI, with a 47% conception rate in the first cycle. Our own unpublished experience confirms these results.

In 1976, Shulman reported the successful use of corticosteroids to treat a man with autoimmunity to sperm.144 Although various degrees of success have subsequently been described, most of these earlier reports suffer from their inability to document the change in antibody binding on the sperm themselves (Table 12).125, 145, 146, 147, 148, 149, 150 Success of treatment was often not judged on the basis of an observed quantitative change in the status of autoimmunity but rather on the rate of pregnancy following treatment. However, in retrospectively analyzing the pregnancy outcome of 108 women whose mates were found to have autoimmunity to sperm but were not treated during a 2-year period, spontaneous conception rates varied with the proportion of sperm antibody coated.125 When more than 50% of sperm were bound with immunoglobulins, 22% of women conceived, whereas 45% conceived when fewer than 50% of sperm in the ejaculate were immunoglobulin coated. The results were even more distinct in couples whose sole cause of infertility was the man's autoimmunity to sperm. Here, pregnancy rates were 15.6% if the majority (more than 50%) of sperm were antibody coated, and rose to 63% if less than 50% of sperm were bound. Given these well-documented spontaneous conception rates, depending on the extent of autoimmunity to sperm, the use of pregnancy as a validation of treatment is misleading, without adequate placebo controls.

Table 12. Pregnancy rates after corticosteroid treatment of men with immunity to spermatozoa

Investigators and citations


Number of pregnancies/number of men treated (%)

DeAlmeida and Jouannet150

Dexamethasone, 2 or 3 mg/day × 9–13 weeks, then 7 weeks taper

3/14 (21%)

Hendry et al.145

Methylprednisone, 96 mg/day × 7 days starting on CD 21 of wife's menstrual cycle

14/45 (31%)

Hargreave and Elton147

Methylprednisone, 96 mg/day × 7 days starting on CD 21 of wife's menstrual cycle

5/13 (38%)

Shulman and Shulman146

Methylprednisone, 96 mg/day × 7 days starting on CD 21 of wife's menstrual cycle

31/71 (44%)

Hendry W et al.148

Prednisolone, 20 or 40 mg twice a day on CD 1 of wife's menstrual cycle; then 5 mg/day on CD 11 and 12 for 9–12 cycles

25/76 (33%)

Alexander et al.149

Prednisolone, 20 mg 3 times/day

7/19 (37%)

 Ayvaliotis et al.125

No treatment over 2 years retrospective period of observation



CD, cycle day.
† Greater than 50% of sperm antibody coated as determined by direct immunobead binding.
‡ Less than 50% of sperm antibody coated.

A single study has documented a variable suppression of antisperm antibodies within seminal plasma in some men treated with corticosteroids.150 A single study has also reported changes in the amount of antibody bound to sperm.151 Whether the degree of suppression of autoimmunity in these cases would be sufficient to increase the number of antibody-free sperm in the ejaculate to a clinically significant level remains unproven. Given the side-effects of corticosteroids, such as mood changes, leg muscle cramps, hypertension, reactivation of ulcers, alterations of glucose tolerance, and rare but severe aseptic hip joint necrosis, one must remain conservative about their use pending further well-controlled studies.

A rationale for IUI is to place within the uterine cavity a large population of living sperm that were excluded after coitus because of the presence of antisperm antibodies either on their surface or within cervical mucus. In theory, this would increase the likelihood that sperm might enter the fallopian tubes and reach the egg. Using careful sonographic and hormonal monitoring of follicular maturation, insemination can be timed to within a few hours of the expected ovulation. The accuracy of timing is theoretically important in that antibody-bound spermatozoa have a shortened survival time within the female reproductive tract. Pregnancy rates have varied in different clinical series over the range of 20–40%. In theory, the triggering of ovulation by injection of recombinant hCG (once follicular maturation has been confirmed by measurement of serum estradiol and follicular diameters at endovaginal ultrasound scanning) will increase the accuracy of timing of IUI, although there are no current prospective studies to document a difference in conception rates. Conception occurred rapidly within four to six cycles, as in the case of women without antisperm antibodies,152, 153 and appeared to be higher in gonadotropin-stimulated cycles (Table 13).93, 154 These studies have been difficult to interpret, unfortunately, because the diagnosis of immune-mediated infertility is often unclear. Hence, the association of circulating antisperm antibodies in sera of women, in conjunction with impaired sperm survival within cervical mucus, is not necessarily proof of a cause-and-effect relationship. The clinical data do suggest, however, that this approach should be attempted before IVF. In addition, given the relatively low conception rates, these results suggest that antibody-coated sperm may not always reach the fallopian tubes after IUI, despite their placement high within the uterine fundus. Alternatively, they may be unable to fertilize, despite successfully meeting the egg at the site of fertilization, because of the presence of antisperm antibodies in tubal secretions.

Table 13. Conception rates per cycle following IUI in women with humoral antisperm antibodies and impaired postcoital tests*


Cycle number

Number pregnant/number inseminated (% pregnant)

Natural cycle

Clomiphene citrate

Human menopausal gonadotropins


4/67 (6%)

2/25 (8%)

5/28 (18%)


5/62 (8%)

4/23 (17%)

1/20 (5%)




3/15 (20%)




1/11 (9%)




1/8 (12%)





* Fewer than 5 motile sperm per high-power field
(Adapted from Margalioth EJ, Sauter E, Bronson RA et al: Intrauterine insemination as treatment for antisperm antibodies in the female. Fertil Sterile 50:444, 1988. Reproduced with permission of the publisher, The American Fertility Society.)

If IUI fails, IVF currently appears to offer an excellent chance of conception in couples with documented immunities to sperm. Antisperm antibodies within follicular fluid can be removed by washing the cumulus–oocyte complex, and any residual immunoglobulins that may remain within the cumulus oophorus that surrounds the egg do not usually appear to significantly interfere with sperm penetration. While older studies, such as that of Yovich et al.(1984),155 reported lower rates of fertilization in vitro when patient sera was used to supplement culture media, IVF in women with antisperm antibodies has been successful and rates in serum-free medium have been nearly comparable to those in their absence.156, 157, 158

In men with autoimmunity to sperm, as previously noted, the diminished number of antibody-coated sperm entering cervical mucus after coitus markedly lowers the chances that the gametes will meet. IVF circumvents this problem of sperm transport and ensures the meeting of spermatozoa and egg (Table 14). Fertilization rates achieved by sperm obtained from men with autoimmunity to sperm have been high in several reports, suggesting that impaired sperm transport (functional oligospermia) has been the primary basis of their infertility.143, 159, 160, 161 In contrast to women with immunities to sperm, however, in whom follicular fluid containing antisperm antibodies can be washed from the egg, immunoglobulins in the ejaculates from men with autoimmunity to sperm remain bound to the sperm surface after their recovery from seminal fluid. Although antibodies present on the sperm tail do not significantly prevent fertilization in vitro, sperm head-directed antibodies have the potential to alter the spermatozoan egg-penetrating ability, as previously described in both the hemizona assay and the zona-free hamster egg penetration test. Fortunately, these effects may only become apparent when more than 70% of the sperm population used in IVF are coated with immunoglobulins.131, 132, 158, 162 In theory, results will also depend on the sperm antigen to which these antibodies are directed. Should they be directed against antigens that have no role in fertilization, the process of penetration by the spermatozoon would not be impaired. This has clearly been documented under experimental conditions, after the generation of antisperm monoclonal antibodies.163 Unfortunately, no clinical test can predict this outcome before an actual attempt at IVF. Hence, when head-directed antisperm antibodies are detected by direct immunobead binding on all sperm, intracytoplasmic sperm injection (ICSI) should be performed, to ensure high rates of fertilization.131, 164, 165

While the argument has been made that the routine testing for antisperm antibodies is not cost effective in the use of ART, given its low incidence and the high likelihood of fertilization, this is a value judgment. Should one wait for the occasional case of failed fertilization to perform tests for antisperm antibodies retrospectively, as has been suggested? How does one judge the emotional cost to the couple who have gone through these procedures and failed to conceive? Had an immunobead binding test been performed, for a very small individual cost relative to the total cost of an IVF cycle, these couples could have been placed in a high risk category for failed IVF and the need for ICSI discussed.

Table 14. Effect of antisperm antibodies on in vitro fertilization rates in 32 men with autoimmunity to spermatozoa


Percentage spermatozoa coated with immunoglobulin*

>80% IgA & IgG

>80% IgA

>80% IgG

<80% IgA & IgG

Percentage of eggs fertilized (no. of eggs inseminated)

25% (102)

30% (10)

89% (29)

73% (75)

*As determined by direct immunobead binding.
(Adapted from DeAlmeida M, Gazagne I, Jeulin C et al: In vitro processing of sperm with auto-antibodies and in vitro fertilization results. Hum Reprod 4:49, 1989; and Clarke GN, Lopata A, McBain JC et al: Effect of sperm antibodies in males in human in vitro fertilization (IVF). Am J Reprod Immunol 8:62, 1985.)



Tung KSK, Menge AC: Sperm and testicular autoimmunity. In Rose NR, MacKay R (eds): The Autoimmune Diseases. New York, Academic Press, pp 537–590, 1985



Clarke GN, Elliot P, Smala C: Detection of sperm antibodies in semen using the immunobead test: A survey of 813 consecutive patients. Am J Reprod Immunol 7: 118, 1985



Ogra PH, Ogra SS: Local antibody response to polio vaccine in the human female genital tract. J Immunol 110: 1307, 1973



Waldman RLT, Cruz JM, Rone FS: Immunoglobulin levels and antibody to Candida albicans in human cervico-vaginal secretions. Clin Exp Immunol 10: 427, 1972



El-Demiry M, James R: Lymphocyte subsets and macrophages in the male genital tract in health and disease. Eur J Urol 14: 226, 1988



Witkin SS: Mechanisms of active suppression of the immune response to spermatozoa. Am J Reprod Immunol 17: 61, 1988



Bratanov K: Reproductive immunology: Historical roots, achievements and prospects. In Isojima S, Billington WD (eds): Reproductive Immunology, pp 1–18. New York. Elsevier, 1983



Edwards RG: Immunologic control of fertility in female mice. Nature 203:50 1963



Katsh S: Infertility in female guinea pigs induced by injection of homologous sperm. Am J Obstet Gynecol 78: 276, 1959



McLaren A: Immunologic control of fertility in female mice. Nature 201: 583, 1964



Menge AC, Peegel H, Riolo ML: Sperm factors responsible for immunologic induction of pre and post fertilization infertility in rabbits. Biol Reprod 20: 93, 1979



Freund J, Lipton MM, Thompson GE: Aspermatogenesis in the guinea pig induced by testicular tissue and adjuvants. J Exp Med 97: 711, 1952



Rumke P, Hellinga G: Auto-antibodies to spermatozoa in sterile men. Am J Clin Pathol 32: 357, 1959



Franklin RR, Dukes CD: Antispermatozoal antibody and unexplained cases of sterility in women. Am J Obstet Gynecol 89: 6, 1964



Fjallbrant B: Sperm antibodies and sterility in men. Acta Obstet Gynecol Scand (suppl) 47: 89, 1968



Isojima S, Li TS, Ashitaka Y: Immunologic analysis of sperm immobilizing factor found in sera of women with unexplained infertility. Am J Obstet Gynecol 101: 677, 1968



Bronson RA, Cooper GW, Rosenreid DL: Sperm antibodies: Their role in infertility. Fertil Steril 42: 171, 1984



Cooper NR: The complement system. In Stites DP, Stobo JB, Wells JV (eds): Basic and Clinical Immunology, 6th ed, pp 114–127. Norwalk, Appleton & Lange, 1987



Bronson RA, Cooper GW, Rosenfeld DL: Correlation between regional specificity of antisperm antibodies to the spermatozoan surface and complement-mediated sperm immobilization. Am J Reprod Immunol 2: 222, 1982



Tung KSK, Cooke WD Jr, McCarthy TA et al: Human sperm antigens and antisperm antibodies. Part II. Age related incidence of antisperm antibodies. Clin Exp Immunol 25: 72, 1976



Hjort T, Hansen RB: Immunofluorescent studies on human spermatozoa, Part I. The detection of different spermatozoal antibodies an their occurrence in normal and infertile women. Clin Exp Immunol 8: 9, 1971



Landers DV, Bronson RA, Pavia CS: Reproductive Immunology. In Stites DP, Terr AI (eds): Basic Human Immunology, pp 200–216. Norwalk, Appleton & Lange, 1990



Haas GG Jr, D'Cruz OJ: Quantitation of immunoglobulin G on human sperm. Am J Reprod Immunol 20: 37, 1989



Jager SS, Kremer J, Van Slochteren-Draaisma T: A simple method of screening for antisperm antibodies in the human male: Detection of spermatozoal surface IgG with the direct mixed agglutination reaction carried out in the untreated fresh human semen. Int J Fertil 23: 12, 1978



Bronson RA, Cooper GW, Rosenfeld DL: Membrane-bound sperm specific antibodies. Their role in infertility. In Vogel H, Jagiello G (eds): Bioregulators in Reproduction. p 526. New York, Academic Press, 1981



Clarke GN, Stojanoff A, Cauchi MN: Immunoglobulin class of sperm-bound antibodies in semen. In Bratanov K (ed): Immunology of Reproduction. pp 482–485. Sophia, Bulgarian Academy of Sciences Press, 1982



Bronson RA: Immunobead binding: Present and future uses. In Mathur S, Fredricks C (eds): Perspectives in Immunoreproduction. p 102. New York, Hemisphere, 1988



Bronson RA, Cooper GW, Hjort T et al: Antisperm antibodies detected by agglutination immobilization, microcytoxicity and immunobead binding assays. J Reprod Immunol 8: 279, 1985



Kibrick S, Belding DL, Merrik B: Methods for the detection of antibodies against mammalian spermatozoa. Part II. A gelatin agglutination test. Fertil Steril 3: 430, 1952



Friberg J: Immunological studies on sperm agglutinating sera from men. Acta Obstet Gynecol Scand (suppl) 36: 43, 1974



Rose NR, Hjort T, Rumke P et al: Techniques for detection of iso- and autoantibodies to human spermatozoa. Clin Exp Immunol 23: 175, 1976



Mettler L, Czuppon AB, Alexander N et al: Antibodies to spermatozoa and seminal plasma antigens detected by various enzyme-linked immunosorbent (ELISA) assays. J Reprod Immunol 8: 30, 1985



Bronson RA, Cooper GW, Witkin SS: Detection of spontaneously occurring sperm-directed antibodies in infertile couples by immunobead binding and enzyme-linked immunosorbent assay. Ann NY Acad Sci 438: 504, 1984



Clarke GN: Lack of correlation between the immunobead test and the enzyme-linked immunosorbent assay for sperm antibody detection. Am J Reprod Immunol 18: 44, 1988



Pavia CS, Stites DP, Bronson RA: Reproductive immunology, In Stites DP, Stobo JD, Wells JU (eds): Basic and Clinical Immunology. 6th ed. p 619. Norwalk, Appleton & Lange, 1987



Hellstrom WJG, Overstreet JW, Samuels SJ et al: The relationship of circulating antisperm antibodies to sperm surface antibodies in infertile men. J Urol 140: 1039, 1988



Bronson RA, Cooper GW, Rosenfeld DW et al: Comparison of antisperm antibodies in homosexual and infertile men with auto-immunity to spermatozoa. Presented at the 30th annual meeting of the Society for Gynecologic Investigation, Washington, DC. March 17–20, 1983



Mesteky J, McGhee JR: Immunoglobulin A (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 40: 153, 1987



Wira CR, Stern JE: Endocrine regulation of the mucosal immune system in the female reproductive tract: Control of IgA, IgG and secretory components during the reproductive cycle, at implantation and throughout pregnancy. In Pasqualini R, Scholler R (eds): Hormones and Fetal Pathophysiology, New York, Marcel Decker, 1992



Fowler JE Jr, Mariano M: Immunologic response of the prostate to bacteriuria and bacterial prostatis, Part II. Antigen specific immunoglobulin in prostatic fluid. J Urol 128: 105, 1982



Kutteh WH, Hatch KD, Blackwell RE et al: Secretory immune system of the female reproductive tract, Part I. Immunoglobulin and secretory component-containing cells. Obstet Gynecol 71: 56, 1988



Kutteh WH, Blackwell RE, Gore H et al: Local immune system in normal and infected human fallopian tube. Fertil Steril 54: 55, 1990



Wira CR, Sandoe CP: Specific IgA and IgG antibodies in the secretions of the female reproductive tract: Effects of immunization and estradiol on expression of this response in vivo. J Immunol 138: 4159, 1987



Cooper GW, Bronson RA: Characterization of humoral antibodies reactive with spermatozoa, N-acetyl galactose-amine and a putative blood group antigen in seminal plasma. Fertil Steril 53: 888, 1990



Bronson RA, Cooper GW, Rosenfeldd DL: Sperm antibodies: Their role in infertility. Fertil Steril 42: 171, 1984



Bronson RA, Tung KSK: Spermatozoa antibodies: Detection and clinical significance. In Tan E (ed): Laboratory Manual of Clinical Immunology (in press)



Bronson RA. What the sperm says and the egg hears - A tale of two proteins and more. Am. J. Reprd. Immunol. 357-364, 2009.



Primakoff P, Lathrop W, Bronson RA: Identification of human sperm surface glycoproteins recognized by autoantisera from immune infertile men, women and vasectomized men. Biol Reprod 42: 929, 1990



Bronson RA, Cooper GW, Phillips DM: Effects of antisperm antibodies on human sperm ultrastructure and function. Hum Reprod 4: 653, 1989



Aitkin RJ, Hulme MJ, Henderson CT et al: Analysis of the surface labelling characteristics of human spermatozoa and the interaction with antisperm antibodies. J Reprod Fertil 80: 473, 1987



Mahony MC, Blackmore PF, Bronson RA, Alexander N J: Inhibition of human sperm: Zona pellucida tight binding in the presence of antisperm antibody positive polyclonal patient sera. J Reprod Immunol 19: 287, 1991



Burkman LJ, Coddington CC, Franken DR et al: The hemizona assay (HZA), development for the binding of human spermatozoa to the human hemizona pellucida to predict fertilization potential. Fertil Steril 49: 608, 1988



Bronson RA: Immunologic infertility. In Rajfer J (ed): Infertility and Impotence, pp 93–100. Chicago, Year Book Medical Publishers, 1990



Jager S, Kremer J, Kuiken J et al: Induction of the shaking phenomenon by pretreatment of spermatozoa with sera containing antisperm antibodies. Fertil Steril 36: 784, 1984



Wang C, Baker HWG, Jennings MG et al: Interactions between cervical mucus and sperm surface antibodies. Fertil Steril 44: 484, 1985



Bronson RA, Cooper GW, Rosenfeld DL: Auto-immunity to spermatozoa: Effects on sperm penetration of cervical mucus as reflected by post-coital testing. Fertil Steril 41: 609, 1984



Fjallbrant B: Interaction between high levels of sperm antibodies, reduced penetration of cervical mucus by spermatozoa and sterility in men. Acta Obstet Gynecol Scand 47: 102, 1968



Jager S, Kremer J, Kuiken J et al: The significance of the Fc part of antispermatozoal antibodies for the shaking phenomenon in the sperm-cervical mucus contact test. Fertil Steril 36: 792, 1981



Bronson RA, Cooper GW, Rosenreid DL et al: The effect of IgA1 protease on immunoglobulins bound to the sperm surface and sperm cervical mucus penetrating ability. Fertil Steril 47: 985, 1987



Bronson RA, Cooper GW: Effects of sperm-reactive monoclonal antibodies on the cervical mucus penetrating ability of human spermatozoa. Am J Reprod Immunol Microbiol 14: 59, 1987



Price RJ, Boettcher B: Presence of complement in cervical mucus and its possible relevance to infertility in women with complement-dependent sperm immobilizing antibodies. Fertil Steril 31: 61, 1979



Veaute C, Furlong LI, BronsonR, Harris JD, Vazquez-Levin MH. Acrosin antibodies and infertility. I. Detection of antibodies towards proacrosin/acrosin in women consulting for infertility and evaluation of their effects upon sperm protease activities. Fertil. Steril. 91: 1245-1255, 2009.



Ishahakia MA: Characterization of baboon testicular antigens using monoclonal antisperm antibodies. Biol Reprod 39: 889, 1988



Dym M: The fine structure of the monkey (Macaca) sertoli cell and its role in maintaining the blood-testis barrier. Anat Rec 175: 639, 1973



Tung KSK, Yule TD, Mahi-Brown CA et al: Distribution of histopathotogy and Ia positive cells in actively induced and passively transferred experimental autoimmune orchitis. J Immunol 138: 752, 1987



Mahi-Brown CA, Yule TD, Tung KSK: Evidence for active immunological regulation in prevention of testicular autoimmune disease independent of the blood-testis barrier. Am J Reprod Immunol 16: 165, 1988



Tung KSK. Autoimmune disease in the testis and ovary. In: Reproductive Immunology, (Eds) Bronson, RA, Alexander NJ, Anderson D, Branch DW, Kutteh, WH Blackwell Science, 1996, pp 153-170.



James K, Hargreave TB: Immunosuppression by seminal plasma and its possible clinical significance. Immunol Today 5: 357, 1984



Lord EK, Senabaugh GF, Stites DP: Immunosuppressive activity of human seminal plasma. Part I. Inhibition of in vitro lymphocyte activation. J Immunol 118: 1706, 1977



Bronson R. Biology of the male reproductive tract:Its cellular and morphological considerations. Am. J. Reprod. Immunol. 65: 212-219, 2011



Quayle AJ, Kelly RW, Hargreave TB et al: Immunosuppression by seminal prostaglandins. Clin Exp Immunol 75: 387, 1989



Williams-Ashman HG, Lockwood DH: Role of polyamines in reproductive physiology and sex hormone action. Ann NY Acad Sci 171: 882, 1970



Mukherjee DC, Agrawal AK, Manjunath I et al: Suppression of epididymal sperm antigenicity in the rabbit by uteroglobulin and transglutaminase. Science 219: 989, 1983



Witkin SS, Richards JM, Bangiovanni M et al: An IgG Fc binding protein in seminal fluid. Am J Reprod Immunol 3: 23, 1983



Hertenbach U, Shearer GM: Germ cell induced immune suppression in mice: Effect of inoculation of syngeneic spermatozoa on cell-mediated immune responses. J Exp Med 155: 1719, 1982



Allen RD, Roberts TK: Role of spermine in the cytotoxic effects of seminal plasma. Am J Reprod Immunol Microbiol 13: 4, 1987



Szymaniec S, Quayle AJ, Hargreave TB et al: Human seminal plasma suppresses lymphocyte responses in vitro in serum free medium. J Reprod Immunol 12: 191, 1987



Peterson BH, Lammel CJ, Stites DP et al: Human seminal plasma inhibition of complement. J Lab Clin Med 96: 582, 1980



Hutter H., Dohr G. HLA expression on immature and mature human germ cells. J. Reprod. Immunol. 38:101-122, 1998.



Pang P-C, Tissot B, Drobnis EZ, Sutovsky P, Morris HR, Clark GF, Dell A. Expression of bisecting type and Lewis x/Lewis y terminated N-gycans on human sperm. J. Biol. Chem. 282: 36593-36602, 2007.



Burden HP, Holmes CBH, Persad R, Whittinton K. Prostasomes - their effects on human male reproduction and fertility. Hum. Reprod. Update 12: 283-292, 2006.



Palmerini CA, Saccardi C, Carlini E, Fabiani R, Arienti G. Fusion of prostasomes to human spermatozoa stimulates the acrosome reaction. Fertil.Steril. 80: 1181-1184, 2003



Kitamura M, Namiki M, Matsumiya K, Tanaka K, Matsumoto M, Hara T, Kiyohara H, Okabe M, Okuyama A, Seya T. Membrane cofactor protein (CD46) in seminal plasma is a prostasome-bound form with complement regulatory activity and measles virus neutralizing activity. Immunology 84: 626-632, 1995.



Tarazona R, Delgado E, Guarnizo RG, Morgado S, Saanchez-Correa B, Gordillo JJ, DeJulian J, Casado JG. Human prostasomes express CD48 and interfere with NK cell function. Immunobio. 216: 41-46, 2011.



Menge AC, Peegel H: Antibody activities of serum and uterine fluid samples from rabbits isoimmunized against sperm factors. Arch Androl 4: 171, 1980



Menge AC, Burkons DM, Friedlander GE: Occurrence of embryonic mortality in rabbits iso immunized against semen. Int J Fertil 17: 93, 1972



Menge AC, Naz RK: Immunologic reactions involving sperm cells and preimplantation embryos. Am J Reprod Immunol Microbiol 18: 17, 1988



Anderson DJ, Johnson PM, Alexander NJ et al: Monoclonal antibodies to human trophoblast and sperm antigens. J Reprod Immunol 10: 231, 1987



Gaunt SJ: Spreading of a sperm surface antigen within the plasma membrane of the egg after fertilization in the rat. J Embryol Exp Morphol 75: 259, 1985



Hamilton MS: Maternal immune response to oncofetal antigens. J Reprod Immunol 5: 249, 1983



Witkin SS, Chaudry A: Circulating interferon in women sensitized to sperm: New mechanisms of infertility. Fertil Steril 52: 867, 1989



Jones WR: Immunologic infertility: Fact or fiction? Fertil Steril 33: 577, 1980



Margalioth EJ, Sauter E, Bronson RA et al: Intrauterine insemination as treatment for antisperm antibodies in the female. Fertil Steril 50: 441, 1988



Anderson DJ, Hill JA: Cell mediated immunity in infertility. Am J Reprod Immunol 17: 22, 1988



Kamat BR, Isaacson PG: The immunocytochemical distribution of leukocytic subpopulation in human endometrium. Am J Pathol 127: 66, 1987



Bulmer JM, Sunderland CA: Immunohistological characterization of lymphoid cell populations in the early human placental bed. Immunology 52: 349, 1984



Xu C, Hill JA, Anderson DJ: Identification of T lymphocyte subpopulations in normal and abnormal human endometrial biopsies. Society for Gynecologic Investigation, Atlanta, Georgia, March 18–21, 1987



Hill JA, Cohen J, Anderson DJ: The effects of lymphokines and monokines human sperm fertilizing ability in the hamster egg penetration test. Am J Obstet Gynecol 160: 1154, 1989



Mahi-Brown CA, Yanagimachi R, Hoffman JC et al: Fertility control in the bitch by active immunization with porcine zona pellucida: Use of different adjuvants and patterns of estradiol and progesterone levels in estrous cycles. Biol Reprod 32: 761, 1985



Dunbar BS, Lo C, Powell LJ et al: Use of synthetic peptide adjuvant for the immunization of baboons with denatured and deglycosylated pig zona pellucida glycoproteins. Fertil Steril 52: 31 l, 1989



East IJ, Mattison DR, Dean J: Monoclonal antibodies to the major protein of the murine zona pellucida: Effects on fertilization and early development. Dev Biol 104: 49, 1984



Shivers CA, Dunbar BS: Autoantibodies to zona pellucida: A possible cause for infertility in women. Science 197: 1082, 1977



Sacco AG, Moghissi KS: Antizona pellucida activity in human sera. Fertil Steril 31: 503, 1979



Karuchi H, Wakimoto H, Sakumoto T et al: Detection of anti-zona activities in human sera by passive hemagglutination reaction. Fertil Steril 41:901, 1984



Kamada M, Hasehe H, Irahara M et al: Detection of antizona pellucida activities in human sera by the passive hemagglutination reaction. Fertil Steril 41: 901, 1984



Dunbar B: Ovarian antigens and infertility. Am J Reprod Immunol 21: 28, 1989



Dakhno FU, Hjort T, Grischenko VI: Evaluation of immunofluorescence on pig zona pellucida for detection of antizona antibodies in human sera. J Reprod Immunol 2:281, 1980



Tung KSK: Human sperm antigens and antisperm antibodies, Part 1. Studies on vasectomy patients. Clin Exp Immunol 20: 93, 1975



Alexander NJ, Free MJ, Paulsen CA et al: A comparison of blood chemistry, reproductive hormones and the development of antisperm antibodies after vasectomy in men. J Androl 1:40. 1980



Meinertz H, Bronson RA (1988) Detection of antisperm antibodies on the surface of motile spermatozoa, comparison of the immunobead binding technique (IBT) and the mixed agglutination reaction (MAR). Am J Reprod Immunol 18, 120-123.



Patrizio P, Moretti-Rojas I, Ord T, Balcemeda J, Silber S, Ash RH. (1989) Low incidence of antisperm antibodies in men with congenital absence of the vas deferens. Fertil Steril 52, 1018-1021.



D'Cruz OJ, Haas, GG Jr, de la Rocha R, Lambert H. (1991) Occurrence of serum antisperm antibodies in patients with cystic fibrosis. Fertil Steril 63, 87-91.



Bronson RA, O'Connor WJ, Wilson TA, Bronson SK, Chasalow FI, Droesch K. (1992) Correlation between puberty and the development of auto-immunity to spermatozoa in men with cystic fibrosis. Fertil Steril 58, 1199-1204.



Alexander NJ, Clarkson TB, Fulgham DL: Circulating immune complexes and antisperm antibodies in vasectomized and vasovasotomized macaques. Ann NY Acad Sci 438: 5011, 1984



Lobatto S, Daha MR, Veerman AA et al: Clearance of soluable aggregates of immunoglobulin G in healthy volunteers and chimpanzees. Clin Exp Immunol 68: 133, 1987



Alexander NJ: Vasectomy: Long-term effects in the rhesus monkey. J Reprod Fertil 31: 399, 1972



Marsh LD, Alexander NJ: Vasectomy: Effects on the efferent ducts in Macaca mulatta. Am J Pathol 107: 310, 1982



Alexander NJ, Fulgham DL, Plunkett ER et al: Antisperm antibodies and circulating immune complexes of vasectomized men with and without coronary events. Am J Reprod Immunol Microbiol 12: 38, 1986



Alexander NJ, Clarkson TB: Vasectomy increases the severity of diet-induced athero-sclerosis in Macaca fasicularis. Science 201: 538, 1978



Goldacre MJ, Holford TR, Vessey MP: Cardiovascular disease and vasectomy. N Engl J Med 308: 805, 1983



Massey FJ et al: Vasectomy and health: Results from a large cohort study. JAMA 252: 1023, 1984



Beer AE, Neaves WB: Antigenic status of semen from the viewpoints of the female and male. Fertil Steril 29: 3, 1978



Vander Merwe JP, Kruger TF, Windt ML et al: Treatment of male sperm autoimmunity by using the gamete intrafallopian transfer procedure with washed spermatozoa. Fertil Steril 53: 682, 1990



Bronson, RA, Tung, KSK (1992) Human spermatozoan antibodies: detection nand clinical significance. In: Rose, NR, deMacario, REC, Fahey, JL, et al (Eds.), manual of Clinical Laboratory Immunology. American Society for Microbiology, Washinton, D.C., pp. 775-780.



Ayvaliotis B, Bronson, RA, Rosenfeld, DL, Cooper, GW (1985) Conception rates in couples where auto-immunity to sperm is detected. Fertil. Steril. 43, 739-742.



Parr, MB, Parr, EL 1996. Immunoglobulins in the female genital tract. In: Bronson, RA, Alexander, NJ, Anderson D, Branch DW, Kutteh, WH (Eds.) Reproductive Immunology. Blackwell Science, Cambridge, MA, pp 175–208.



Rajah SV, Parslow JM, Howell R., Hendry WF (1993) The effects on in vitro fertilization of autoantibodies to spermatozoa in subfertile men. Hum Reprod 8: 1079-1082



Acosta AA, van der Merwe JP, Doncel G. et al. (1994) Fertilizatio efficiency of morphologically abnormal spermatozoa in assisted reproduction is furter impaired by antisperm antibodies on the male pertner's sperm. Fertil Steril 62: 826-833.



Padigas K, Hemmings R, Falcone TN, Miron P (1994) The effect of antisperm autoantibodies in male and female partners undergoing in vitro fertilization-embryo transfer. Fertil Steril 62, 363-369.



Vazques-Levin, MH, Notrica JA, Polak de Freid E (1997) Male immunologic infetility: sperm performance on in vitro fertilization. Fertil Steril 68, 673-681.



Lahteenmaki A, Reima I, Hovatta O (1995) Treatment of severe male immunologic infertiilty by intracytoplasmic sperm injection. Hum Reprod 10, 2824-2828.



Yeh WR, Acosta A, Seltman HJ, Doncel G (1995) Impact of immunoglobulin isotype and sperm surface location of antisperm antibodies on fertilization in vitro in the human. Fertil Steril 63: 1287-1292.



Hendry WF, Hughes L, Scammell G et al. (1990) Comparison of prednisolone and placebo in subfertile men with autoantibodies to spermatozoa. Lancet 335, 85-88



London SN, Haney AF, Weinberg JB (1985) Macrophages and infertility:enhancement of human macrophage-mediated sperm killing by antisperm antibodies. Fertil Steril 43: 274-278.



Guzick, D.S., Carson, S.A., Coutifaris, C., Overstreet, J.W., Factor-Litvak, P., Steinkampf, M.P., Hill, J.A., Mastroianni, L., Buster, J.E., Nakajima , S.T., Dogel, D.L., Canfield, R.E. (1999) Efficiency of superovulation and intrauterine insemination in the treatment of infertility. New Engl.J.Med. 340, 177–183.



Haas, G.G., Jr., D'Cruz, O.J. (1988) Effect of repeated washing on sperm-bound immunoglobulin G. J. Androl. 9, 190-196.



Bronson, R.A. (1988) Immunity to sperm and in vitro fertilization (Editorial). J. In Vitro Fertilization. Embryo Tranplant. 4, 195-197.



Jeulin C, Soumah A. Da Siva G., DeAlmeida, M. (1989) In-vitro processing of sperm with autoantibodies:analysis of sperm populations. Hum. Reprod. (1989) 4, 44-48.



Elder, K.T., Wick, K.L. Edwards, R.G. (1990) Seminal plasma anti-sperm antibodies and IVF: the effect of semen sample collection in 50% serum. Hum. Reprod. 5, 179-184



Fowler, J.E.jr. (1996) Antibody response to bacterial innfections of the male urogenital tract. In. Bronson, R.A., Alexander, N.J., Anderson, D., Branch, D.W., Kuteh, W.H. (Eds.) Reproductive Immunology. Blackwell Science, Cambridge, MA, pp 513-531.



Haas, G.G.Jr., (1991) Male infertiilty and immunity. In Lipshutz, L.J., Howards, S.S. Jr.(Eds.) Infertility in the Male, Moseby Yearbook, St. Louis, MO, pp277-296.



Francavilla, F., Romano R., Santucci R., Marrone V., Carrao G. (1992) Failure of intrauterine insemination in male immunological infertility in cases in which all spermatozoa are antibody-coated. Fertil. Steril. 58, 587-592.



Ombelet W., Vandeput H., Janssen M, Cox, A., Vossen C., Poliet H, Steeno O, Bosmans, E. (1997) Treatment of male infertility due to sperm surface antibodies: IUI or IVF? Hum. Reprod. 12, 1165-1170.



Shulman S: Treatment of immune male infertility with methyl prednisolone. Lancet 2: 1243, 1976



Hendry WF, Stedronska J, Parslow J, Hughes L. The results of intermittent high dose steroid therapy for male infertility due to antisperm antibodies. Fertil Steril. 1981 Sep;36(3):351-5.



Shulman JF, Shulman S: Methylprednisolone treatment of immunologic infertility in the male. Fertil Steril 38: 591, 1982



Hargreave T, Elton RA: Fertil Steril 38:586, 1982



Hendry WF, Treehuba K, Hughes L et al: Cyclic prednisolone therapy for male infertility associated with auto-antibodies to spermatozoa. Fertil Steril 45: 249, 1986



Alexander NJ, Sampson JH, Fulgham DL: Pregnancy rates in patients treated for antisperm antibodies with prednisone. Int J Fertil 28: 63, 1983



DeAlmeida M, Jouannet P: Dexamethasone therapy in infertile men with auto-antibodies: Immunological and sperm follow-up. Clin Exp Immunol 44: 507, 1981



Haas GG Jr, Manganiello P: A double blind, placebo-controlled study of the use methylprednisolone in infertile men with sperm-associated immunoglobulins. Fertil Steril 47: 295, 1987



Haas GG: Immunological infertility. Obstet Gynecol Clin North Am 14: 1069, 1987



Kemmenn E, Bohrer M, Sheldon R et al: Active ovulation management increases the monthly probablity of pregnancy occurrence in ovulatory women who receive intrauterine insemination. Fertil Steril 48: 916, 1987



Dodson WC, Whitesides DB, Hughes CL et al: Superovulation with intrauterine insemination in the treatment of infertility: A possible alternative to gamete intrafallopian transfer and in vitro fertilization. Fertil Steril 48: 441, 1987



Yovich JL, Stanger JD, Day D et al: In vitro fertilization of oocytes from women with serum antisperm antibodies. Lancet 1: 369, 1984



Vazquez-Levin M. Kaplan P., Guzman I, Grunefeld L., Garrisi G.L., Navot D. (1991) The effect of female antisperm antibodies on in vitro fertilization, embryo development and pregnancy outcomes. Fertil. Steril. 56, 84-88.



Hershlag A., Napolitano B., Cangemi C, et al. (1994) The value of routine screening of female serum for antisperm antibodies in assisted reproductive technology cycles. Fertil. Steril. 61, 867-871.



Diatoh T., Kamada M., Murayama S. Kobayashi T. Maegawa M., Anno T. (1995) High implantation rate and consequently high pregnancy rate by in vitro fertilization-embryo transfer in infertile women with antisperm antibodies. Fertil. Steril. 63,87-91.



Lahteenmaki A. (1993) In vitro fertilization in the presence of antisperm antibodies detected by the mixed antiglobulin reaction (MAR) and the tray agglutination test (TAT). Hum. Reprod. 8, 84-88.



Padigas K., Hemmings R., Falcone T., Miron P. (1994) The effect of antisperm autoantibodies in male or female partners undergoing in vitro fertilization-embryo transfer. Fertil. Steril. 62, 363-369.



Sukchareon N., Keith J. (1995) The effect of the antisperm auto-antibody bound sperm on in vitro fertilization outcome. Amdrologia 5, 281-289.



Clarke G.N. (1988) Sperm antibodies and human fertilization. Am.J.Reprod. Immunol. 17,65-71.



Saling P.M. , Lakosaka K.A. (1985) Mouse sperm antigens that participate in fertilization. II. Inhibition of sperm penetration through zona pellucida using monoclonal antibodies. Biol.Reprod. 33, 527-733.



Nagy Z.P., Verheyen G., Liu J., Joris H., Janssenswillen C., Wisanto A., Devroey P., Van Steirteghem A.C. (1995) Results of 55 intracytoplasmic sperm injection cycles in the treatment of male infertility due to sperm surface antibodies: IUI or IVF? Hum. Reprod. 12, 1165-1170.



Clarke G.N.M., Bourne H., Baker H.W. (1997) Intracytoplasmic sperm injection for treating infertility associated with sperm auto-immunity. Fertil. Steril. 68, 112-117.

Back to Top